Explore the Potential with AI-Driven Innovation
This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We employ our advanced, specialised process to create targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.
Several key aspects differentiate our library:
partner
Reaxense
upacc
Q01844
UPID:
EWS_HUMAN
Alternative names:
EWS oncogene; Ewing sarcoma breakpoint region 1 protein
Alternative UPACC:
Q01844; B0QYK1; Q5THL0; Q92635; Q96FE8; Q96MN4; Q96MX4; Q9BWA2
Background:
The RNA-binding protein EWS, also known as EWS oncogene or Ewing sarcoma breakpoint region 1 protein, plays a pivotal role in transcriptional repression. Its aberrant fusion proteins, resulting from chromosomal translocations, are implicated in the tumorigenic process, potentially disrupting gene expression and activating target genes abnormally.
Therapeutic significance:
EWS protein's involvement in Ewing sarcoma and Angiomatoid fibrous histiocytoma, through specific chromosomal aberrations, highlights its critical role in disease pathogenesis. Understanding the role of RNA-binding protein EWS could open doors to potential therapeutic strategies, offering hope for targeted treatments in these malignancies.